CO7310526A2 - Oral pharmaceutical composition in the form of microspheres and elaboration process - Google Patents

Oral pharmaceutical composition in the form of microspheres and elaboration process

Info

Publication number
CO7310526A2
CO7310526A2 CO15048826A CO15048826A CO7310526A2 CO 7310526 A2 CO7310526 A2 CO 7310526A2 CO 15048826 A CO15048826 A CO 15048826A CO 15048826 A CO15048826 A CO 15048826A CO 7310526 A2 CO7310526 A2 CO 7310526A2
Authority
CO
Colombia
Prior art keywords
microspheres
pharmaceutical composition
oral pharmaceutical
composition
elaboration process
Prior art date
Application number
CO15048826A
Other languages
Spanish (es)
Inventor
Hernandez Gustavo Barranco
Guiza Maria Del Coral Luna
Arroyo Hector Senosiain
Original Assignee
Senosiain S A De C V Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7310526(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Senosiain S A De C V Lab filed Critical Senosiain S A De C V Lab
Publication of CO7310526A2 publication Critical patent/CO7310526A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición en forma de micropartículas que constanprincipalmente de: a) un núcleo inerte; b) una capa deprincipio activo formada por aspersión sobre el núcleoinerte y c) opcionalmente un segundo recubrimiento quecomprende una o más capas de fármaco(s) y/o excipiente(s)farmacéuticamente aceptable(s). Dicha composición es útilpara el tratamiento de condiciones resultantes de retenciónexcesiva de agua y/o electrolitos, enfermedadescardiovasculares, enfermedades renovasculares, diabetes,disfunciones endotelilales, cirrosis, preeclampsia,nefropatía, enfermedad vascular periférica e hipertensión,entre otras.A composition in the form of microparticles consisting primarily of: a) an inert nucleus; b) an active principle layer formed by spraying on the core and c) optionally a second coating comprising one or more layers of pharmaceutically acceptable drug (s) and / or excipient (s). Said composition is useful for the treatment of conditions resulting from excessive retention of water and / or electrolytes, cardiovascular diseases, renovascular diseases, diabetes, endothelial dysfunctions, cirrhosis, preeclampsia, nephropathy, peripheral vascular disease and hypertension, among others.

CO15048826A 2012-08-17 2015-03-04 Oral pharmaceutical composition in the form of microspheres and elaboration process CO7310526A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012009583A MX351059B (en) 2012-08-17 2012-08-17 Oral pharmaceutical composition in the form of microspheres and preparation method.

Publications (1)

Publication Number Publication Date
CO7310526A2 true CO7310526A2 (en) 2015-06-30

Family

ID=50435594

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15048826A CO7310526A2 (en) 2012-08-17 2015-03-04 Oral pharmaceutical composition in the form of microspheres and elaboration process

Country Status (8)

Country Link
CL (1) CL2015000375A1 (en)
CO (1) CO7310526A2 (en)
CR (1) CR20150077A (en)
DO (1) DOP2015000028A (en)
GT (1) GT201500035A (en)
MX (1) MX351059B (en)
PE (1) PE20150710A1 (en)
WO (1) WO2014027334A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2707533C2 (en) 2013-03-27 2019-11-27 Ф. Хоффманн-Ля Рош Аг Genetic markers for prediction of susceptibility to therapy
CN106559998B (en) 2014-07-30 2022-01-25 豪夫迈·罗氏有限公司 Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agents
CN104523710B (en) * 2014-12-30 2018-05-25 石药集团欧意药业有限公司 A kind of bisulfate clopidogrel aspirin Composite Double synusia and preparation method thereof
KR101710441B1 (en) * 2015-12-28 2017-02-28 신풍제약주식회사 Tablet with improved stability and dissolution
WO2018150286A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
CN106821996A (en) * 2017-03-01 2017-06-13 华益药业科技(安徽)有限公司 Enalapril maleate granule and preparation method thereof
BR112020020941A2 (en) * 2018-04-16 2021-03-02 Bristol-Myers Squibb Company apixaban formulations
IL295268A (en) * 2020-02-19 2022-10-01 Nano Pharmasolutions Inc Therapeutic agent nanoparticles and methods of preparation
US11833133B2 (en) * 2020-08-13 2023-12-05 Orient Pharma Co., Ltd. Solid oral pharmaceutical composition
CN113413364A (en) * 2021-05-31 2021-09-21 辰欣药业股份有限公司 Enoxaparin sodium injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976486A1 (en) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
MXPA06010972A (en) * 2006-09-25 2009-04-17 World Trade Imp Export Wtie Ag Process for stabilizing famotidine.
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
MX2007008440A (en) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Combined pharmaceutical composition.

Also Published As

Publication number Publication date
MX2012009583A (en) 2014-02-26
PE20150710A1 (en) 2015-05-28
WO2014027334A2 (en) 2014-02-20
MX351059B (en) 2017-09-29
GT201500035A (en) 2017-10-24
DOP2015000028A (en) 2015-03-15
CL2015000375A1 (en) 2015-07-10
WO2014027334A3 (en) 2014-04-10
CR20150077A (en) 2015-05-13

Similar Documents

Publication Publication Date Title
CO7310526A2 (en) Oral pharmaceutical composition in the form of microspheres and elaboration process
CL2013003331A1 (en) Alteration-proof immediate-release tablet comprising (i) a matrix, and (ii) a plurality of particulate material, comprising an opiate and a polyethylene oxide polymer of more than 20,000 g / mol, where the multiparticulate forms a discontinuous phase within the matrix.
JP2010222367A5 (en)
FI3562486T3 (en) Use of sublingual dexmedetomidine for the treatment of agitation
ES2916604T1 (en) Nrf2 Detection Assays and Related Methods and Compositions
JP2012255026A5 (en)
JP2013522184A5 (en)
PE20130574A1 (en) NEW MODIFIED RELEASE DOSAGE FORMS OF A XANTHINE OXIDOR REDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS
AR075369A1 (en) COMPRESSED FOR COMBINATION THERAPY FOR THE TREATMENT OF VIRAL INFECTIONS.
AR091351A1 (en) BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING
CL2013001591A1 (en) Compounds derived from triazolopyridine; pde10a inhibitors; obtaining process; pharmaceutical composition; and use in the treatment or prophylaxis of psychotic disorders, schizophrenia, anxiety, among other diseases.
RU2015102772A (en) Benzodiazelipas for small cell lung cancer
JP2012519182A5 (en)
CL2015001615A1 (en) A pharmaceutical composition comprising vortioxetine and donepezil together with a pharmaceutically acceptable excipient; and its use for the treatment of cognitive dysfunction, dementia in Alzheimer's disease, cognitive dysfunction associated with depression and schizophrenia, among other diseases.
PE20110943A1 (en) SOLID ORAL FORMULATION OF ALISQUIREN
CL2014002896A1 (en) A pharmaceutical formulation in the form of a coated tablet consisting of a) a nucleus obtained from a co-mixture of mannitol, croscarmellose sodium and at least one active compound, and b) a coating which is applied in the form of an aqueous solution or one containing water and alcohol, and where the tablet disintegrates rapidly in the presence of moisture; and its preparation process.
CL2013000895A1 (en) Pharmaceutical combination comprising a compound derived from imidazo [4,5-c] -quinoline, pik3 / mtor inhibitor, an allosteric mtor inhibitor compound and optionally a pharmaceutically acceptable carrier; pharmaceutical composition; method to improve the effectiveness of the treatment; and its use in a proliferative disease.
AR086395A1 (en) PACKAGE FOR TREATMENT OF PATHOLOGIES
CL2013003176A1 (en) Sustained-release oral pharmaceutical formulation comprising two tablets containing 1000 mg of paracetamol, which is present in a sustained-release layer and another of immediate release, in a proportion of paracetamol per layer of 80-90%: 10-20% , where the unit dose comprises 2000 mg paracetamol.
DE602007011316D1 (en) PHARMACEUTICAL COMPOSITION WITH ANTIPSYCHOTIC, ANTIDEPRESSIVE OR ANTIEPILEPTIC EFFECT WITH REDUCED SIDE EFFECTS
PE20110925A1 (en) GALENIC FORMULATION INCLUDING ALISQUIRENE AND PROCESS FOR ITS PREPARATION THROUGH FELTED EXTRUSION GRANULATION
ECSP11010999A (en) FIXED DOSAGE COMBINATION IN THE FORM OF A TWO-LAYERED TABLET OR A SINGLE LAYER OF ALISQUIRENE AND AMLODIPINE
PE20151282A1 (en) COMBINATION OF MEDICINES INCLUDING PHENYLPHRINE AND PARACETAMOL
DOP2011000267A (en) ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES
JP2015512948A5 (en)